Lb Pharmaceuticals (LBRX) Non Operating Income (2024 - 2026)

Lb Pharmaceuticals' Non Operating Income history runs 3 years deep, the most recent figure standing at $3.0 million for Q1 2026.

• On a quarterly basis, Non Operating Income rose 171.59% year-over-year to $3.0 million in Q1 2026; TTM through Mar 2026 was $8.3 million, a N/A change from a year earlier, with the FY2025 full-year figure at $5.2 million, up 200.75% from the prior year.
• Non Operating Income grew to $3.0 million in Q1 2026 per LBRX's latest filing, from $2.4 million in the prior quarter.
• Across five years, Non Operating Income topped out at $3.0 million in Q1 2026 and bottomed at $469000.0 in Q4 2024.
• The 3-year median for Non Operating Income is $1.8 million (2024), against an average of $1.8 million.
• Biggest YoY gain for Non Operating Income was 411.51% in 2025; the steepest drop was 11.15% in 2025.
• Year by year, Non Operating Income stood at $469000.0 in 2024, then surged by 411.51% to $2.4 million in 2025, then gained by 27.14% to $3.0 million in 2026.
• Per Business Quant, the three latest LBRX Non Operating Income figures stand at $3.0 million (Q1 2026), $2.4 million (Q4 2025), and $1.7 million (Q3 2025).